Claims for Patent: 9,993,553

Summary for Patent: 9,993,553

Title:	Methods and compositions for targeted release of molecules from nanoscale carriers
Abstract:	The present disclosure relates generally to the field of nanoscale materials, and more specifically to the field of nanoscale materials for activating delivered molecules at a target location.
Inventor(s):	Guo; Ting (Davis, CA), Starkewolfe; Zane B. (Davis, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	14/213,148
Patent Claims:	1. A nanoparticle-based method of providing a treatment to a target cell, the method comprising: (a) contacting the target cell with a nanomaterial composition, the nanomaterial composition comprising a nanoparticle linked, via a linker, to a therapeutic molecule, and (b) cleaving the link between the nanoparticle and the therapeutic molecule with irradiation energy of between about 0.1 Gy and 25 Gy to produce a liberated therapeutic molecule, wherein the biological activity of the liberated therapeutic molecule is greater than the biological activity of the nanomaterial composition. 2. The method of claim 1, wherein the nanomaterial composition further comprises a drug base scaffold wherein the drug base scaffold is attached to the linker and the drug base scaffold is attached to the therapeutic molecule. 3. The method of claim 2, wherein the drug base scaffold is a DNA molecule. 4. The method of claim 2, wherein the drug base scaffold comprises a scaffold molecule, and wherein the scaffold molecule is coupled with one to twelve therapeutic molecules. 5. The method of claim 4, wherein the cleavage releases more than one therapeutic molecule. 6. The method of claim 1, wherein the nanoparticle comprises a core comprising a metal. 7. The method of claim 6, wherein the metal is Au. 8. The method of claim 1, wherein the nanoparticle comprises a shell comprising silica. 9. The method of claim 8, wherein the shell has attached, at its surface, PEG ligands. 10. The method of claim 8, wherein the shell has attached, at its surface, targeting moieties. 11. The method of claim 8, wherein the nanomaterial composition further comprises a water layer immediately surrounding the shell comprising silica. 12. The method of claim 1, wherein the linker is a DNA molecule. 13. The method of claim 1, wherein the therapeutic molecule is doxorubicin. 14. The method of claim 1, wherein the irradiation energy is X-rays. 15. The method of claim 1, wherein the target cell is a cancer cell. 16. The method of claim 1, wherein the irradiation energy produces electrons or reactive oxygen species that participate in the link cleaving. 17. The method of claim 1, wherein the linker is directly coupled to the nanoparticle. 18. A nanoparticle-based method of providing a treatment to a living system, the method comprising: (a) administering to the living system a nanomaterial composition, the nanomaterial composition comprising a nanoparticle linked, via a linker, to a therapeutic molecule, and (b) irradiating the living system with irradiation energy of between about 0.1 Gy and 25 Gy sufficient to cleave the link between the nanoparticle and the therapeutic molecule to produce a liberated therapeutic molecule, wherein the biological activity of the liberated therapeutic molecule is greater than the biological activity of the nanomaterial composition. 19. The method of claim 18, wherein the nanomaterial composition further comprises a drug base scaffold wherein the drug base scaffold is attached to the linker and the drug base scaffold is attached to the therapeutic molecule. 20. The method of claim 19, wherein the drug base scaffold is a DNA molecule. 21. The method of claim 18, wherein the nanoparticle comprises a core comprising a metal. 22. The method of claim 21, wherein the metal is Au. 23. The method of claim 18, wherein the nanoparticle comprises a shell comprising silica. 24. The method of claim 23, wherein the shell has attached, at its surface, PEG ligands. 25. The method of claim 23, wherein the shell has attached, at its surface, targeting moieties. 26. The method of claim 18, wherein the linker is a DNA molecule. 27. The method of claim 18, wherein the therapeutic molecule is doxorubicin. 28. The method of claim 18, wherein the irradiation energy is X-rays. 29. The method of claim 18, wherein the living system comprises a cancer cell. 30. A nanoparticle-based method of providing a treatment to a target cell, the method comprising: delivering a nanomaterial composition to the target cell, the nanomaterial composition comprising a nanoparticle linked, via a linker, to a drug base scaffold to which one or more therapeutic molecules is coupled, and irradiating the nanomaterial composition with irradiation energy of between about 0.1 Gy and 25 Gy to cause one or more therapeutic molecules to decouple from the drug base scaffold. 31. The method of claim 30, wherein at least one of the drug base scaffold and the linker is a DNA molecule. 32. The method of claim 30, wherein at least one additional agent is coupled with the nanomaterial, wherein the additional agent comprises one or more of an antibody, a peptide, a protein, polyethylene glycol, or folic acid. 33. The method of claim 30, wherein the therapeutic molecule includes a molecule selected from the group consisting of Doxorubicin, Fluorouracil, Paclitaxel, Zevalin, Fredericamycin, C-1027, Leinamycin, a protein, a protease, a DNA nuclease, an enzyme, and small RNA.

Details for Patent 9,993,553

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002		2033-03-14